Prognos

Executive Summary

Prognos Health is a leading US-based real-world data (RWD) and analytics company that aggregates, harmonizes, and enriches de-identified clinical and genomic laboratory data from a broad network of partners. Its platform provides life sciences companies with actionable insights for commercial analytics, precision marketing, and patient journey analysis, enabling more targeted and efficient drug development and commercialization. Founded in 2013 and headquartered in New York, Prognos has established itself as a critical infrastructure provider in the healthcare data ecosystem, differentiating itself through the scale and depth of its lab-sourced data and its advanced AI/ML capabilities. The company serves major pharmaceutical and biotech clients, helping them accelerate market access, optimize launch strategies, and improve patient outcomes. As the demand for real-world evidence grows amid value-based care trends, Prognos is well-positioned to capture increasing RWD spend. Prognos operates in a competitive landscape that includes companies like IQVIA, Symphony Health, and Datavant, but its focus on granular lab data and its proprietary harmonization technology provide a unique edge. The company has demonstrated steady growth and has likely attracted interest from strategic acquirers in the healthcare information and life sciences tools space. While private and relatively lean, Prognos has the potential to expand its data network internationally and deepen its analytics offerings. The key risk is data privacy regulation changes and competitive pressure, but the company's defensible data moat and strong client relationships suggest a favorable outlook. Overall, Prognos represents a compelling growth story in the RWD sector with significant upside.

Upcoming Catalysts (preview)

• Q3 2026Expansion of lab partner network (new large-scale partnership)75% success
• Q2 2026Launch of new AI-powered predictive analytics module60% success
• H2 2026Strategic investment or acquisition by a larger healthcare data firm40% success